Bolt Biotherapeutics (NASDAQ:BOLT) is a biotechnology company dedicated to revolutionizing cancer treatment through the development of its innovative immuno-oncology platforms. The company's flagship projects focus on harnessing the body's immune system to target and destroy cancer cells, leveraging its cutting-edge research in the field of Immune-Stimulating Antibody Conjugates (ISACs). Bolt Biotherapeutics aims to pioneer treatments that offer improved outcomes for patients with various types of cancer. With a commitment to innovation and patient care, Bolt Biotherapeutics is actively advancing its pipeline of potential cancer therapies, driven by a deep understanding of the complex interactions within the tumor microenvironment.